# Phase 1 overweight trials recruiting: 82 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 82 trials in phase 1 for overweight that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 overweight trials: 82 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 10 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/overweight

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 82
- Recruiting or not yet: 82
- Read on: November 19, 2026

## Trials

The 25 newest of 82, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944118 | Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in... | Novo Nordisk A/S | Phase 1 | Not yet recruiting | Overweight, Obesity, Type 2 Diabetes | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944118) |
| November 17, 2026 | NCT07940582 | A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or Obesity | Novo Nordisk A/S | Phase 1 | Not yet recruiting | Overweight, Obesity | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940582) |
| November 16, 2026 | NCT07938515 | Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal Impairment and Normal Renal... | Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 1 | Recruiting | Obesity & Overweight | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938515) |
| November 16, 2026 | NCT07937787 | A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With... | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 | Not yet recruiting | Overweight and Obesity, MASH - Metabolic Dysfunction-Associated Steatohepatitis | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937787) |
| November 9, 2026 | NCT07924761 | A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living... | Kailera | Phase 1 | Not yet recruiting | Overweight or Obesity | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924761) |
| November 6, 2026 | NCT07922798 | A Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy Participants | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Not yet recruiting | Overweight , Obesity | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922798) |
| November 6, 2026 | NCT07921316 | Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous... | Amgen | Phase 1 | Not yet recruiting | Obesity, Overweight | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921316) |
| November 4, 2026 | NCT07916194 | A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy Participants | Beijing QL Biopharmaceutical Co.,Ltd | Phase 1 | Not yet recruiting | Overweight, Obesity | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916194) |
| November 4, 2026 | NCT07915245 | A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915245) |
| November 2, 2026 | NCT07911514 | A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 | AstraZeneca | Phase 1 | Not yet recruiting | Healthy Participants | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911514) |
| November 2, 2026 | NCT07908316 | Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After... | Amgen | Phase 1 | Recruiting | Obesity, Overweight | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908316) |
| October 22, 2026 | NCT07890870 | A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity. | iBio, Inc. | Phase 1 | Not yet recruiting | Obesity & Overweight | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890870) |
| October 20, 2026 | NCT07881887 | A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 617 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881887) |
| October 15, 2026 | NCT07877038 | Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function | Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 1 | Not yet recruiting | Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877038) |
| October 15, 2026 | NCT07876531 | A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or... | Pfizer | Phase 1 | Recruiting | Overweight and/or Obesity, Healthy Participants | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876531) |
| October 15, 2026 | NCT07876518 | A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity | Pfizer | Phase 1 | Not yet recruiting | Overweight and/or Obesity | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876518) |
| October 14, 2026 | NCT07873645 | Study of UBT37034 Injection | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Recruiting | Overweight , Obesity | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873645) |
| October 9, 2026 | NCT07868354 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868354) |
| October 2, 2026 | NCT07855133 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855133) |
| September 29, 2026 | NCT07845578 | A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight | Novo Nordisk A/S | Phase 1 | Recruiting | Obesity, Overweight | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845578) |
| September 22, 2026 | NCT07832799 | Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose | Amgen | Phase 1 | Not yet recruiting | Overweight, Obesity | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832799) |
| September 11, 2026 | NCT07815067 | A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815067) |
| September 9, 2026 | NCT07809945 | A Study of IBI3046 in Participants With Overweight or Obesity | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Recruiting | Obesity and Overweight | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809945) |
| September 8, 2026 | NCT07808073 | A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808073) |
| September 8, 2026 | NCT07808060 | A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808060) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 18 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 8 |
| [Shanghai Minwei Biotechnology Co., Ltd](https://specstream.ai/data/clinical-trials/company/shanghai-minwei-biotechnology-co-ltd) | 4 |
| The United Bio-Technology (Hengqin) Co., Ltd. | 3 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 3 |
| [Fujian Shengdi Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/fujian-shengdi-pharmaceutical-co-ltd) | 3 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 3 |
| Kailera | 2 |
| Chendu DIAO Pharmaceutical Group CO., LTD. | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 2 |
| Columbia University | 2 |
| iBio, Inc. | 2 |
| Shenzhen Kangzhe Biotechnology Co., Ltd. | 1 |
| Verdiva Bio Dev Limited | 1 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |
| Beijing QL Biopharmaceutical Co.,Ltd | 1 |
| MBX Biosciences | 1 |
| Suzhou Siran Biotechnology Co.,Ltd. | 1 |
| Corxel Pharmaceuticals | 1 |
| [Daewoong Pharmaceutical Co. LTD.](https://specstream.ai/data/clinical-trials/company/daewoong-pharmaceutical-co-ltd) | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| Shanghai Xitaili Biomedicine Technology co., Ltd. | 1 |
| Shanghai World Leader Pharmaceutical Co., Ltd. | 1 |
| University of Alberta | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 26 |
| China | 23 |
| Australia | 10 |
| Germany | 6 |
| Singapore | 4 |
| Canada | 2 |
| United Kingdom | 2 |
| Japan | 1 |
| Sweden | 1 |
| Slovakia | 1 |
| South Korea | 1 |
| Austria | 1 |
| Denmark | 1 |
| Netherlands | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
- [Abrasives suppliers in the United States](https://specstream.ai/data/businesses/abrasives-suppliers/united-states)
- [Food and beverage distributors in the United States](https://specstream.ai/data/businesses/food-and-beverage-distributors/united-states)
- [Resorts in the United States](https://specstream.ai/data/businesses/resorts/united-states)
- [Career counseling services in the United States](https://specstream.ai/data/businesses/career-counseling-services/united-states)
- [Machinery and tool manufacturers in the United States](https://specstream.ai/data/businesses/machinery-and-tool-manufacturers/united-states)
